{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:45Z","timestamp":1783723485804,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-CE16-0001-01"],"award-info":[{"award-number":["ANR-14-CE16-0001-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jgar.2021.10.030","type":"journal-article","created":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T12:30:03Z","timestamp":1639744203000},"page":"84-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Prodrugs as new therapies against Chagas disease: in vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0747-7760","authenticated-orcid":false,"given":"Guilherme Dias","family":"de Melo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Coatnoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Gouault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Cupif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Renault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Uriac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-3025","authenticated-orcid":false,"given":"Arnaud","family":"Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1659-833X","authenticated-orcid":false,"given":"Paola","family":"Minoprio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.030_bib0001","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00023-19","article-title":"Chagas disease in the United States: a public health approach","volume":"33","author":"Bern","year":"2019","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2021.10.030_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105906","article-title":"Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review","volume":"55","author":"Santos","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2021.10.030_bib0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3201\/eid2501.180646","article-title":"Oral transmission of Trypanosoma cruzi, Brazilian Amazon","volume":"25","author":"Santana","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.030_bib0004","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.pt.2011.06.006","article-title":"Invasion mechanisms among emerging food-borne protozoan parasites","volume":"27","author":"Yoshida","year":"2011","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.jgar.2021.10.030_bib0005","series-title":"Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis. Technical report series n\u00b0975","year":"2012"},{"key":"10.1016\/j.jgar.2021.10.030_bib0006","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jac\/dkz473","article-title":"Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas\u2019 disease","volume":"75","author":"Jackson","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.030_bib0007","article-title":"Revisiting the posttherapeutic cure criterion in Chagas disease: time for new methods, more questions, doubts, and polemics or time to change old concepts?","volume":"2015","author":"Lana","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jgar.2021.10.030_bib0008","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/78651","article-title":"A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase","volume":"6","author":"Reina-San-Martin","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.jgar.2021.10.030_bib0009","doi-asserted-by":"crossref","first-page":"15484","DOI":"10.1074\/jbc.M210830200","article-title":"Biochemical characterization of proline racemases from the human protozoan parasite Trypanosoma cruzi and definition of putative protein signatures","volume":"278","author":"Chamond","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jgar.2021.10.030_bib0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2958.2005.04808.x","article-title":"Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity","volume":"58","author":"Chamond","year":"2005","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.jgar.2021.10.030_bib0011","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1073\/pnas.0509010103","article-title":"Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase","volume":"103","author":"Buschiazzo","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2021.10.030_bib0012","doi-asserted-by":"crossref","first-page":"e60955","DOI":"10.1371\/journal.pone.0060955","article-title":"Combined approaches for drug design points the way to novel proline racemase inhibitor candidates to fight Chagas\u2019 disease","volume":"8","author":"Berneman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.030_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006853","article-title":"Designed mono- and di-covalent inhibitors trap modeled functional motions for Trypanosoma cruzi proline racemase in crystallography","volume":"12","author":"Amaral","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.jgar.2021.10.030_bib0014","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.parint.2013.07.011","article-title":"In vivo imaging of trypanosomes for a better assessment of host\u2013parasite relationships and drug efficacy","volume":"63","author":"Goyard","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.jgar.2021.10.030_bib0015","doi-asserted-by":"crossref","first-page":"14240","DOI":"10.1038\/ncomms14240","article-title":"Esterase mutation is a mechanism of resistance to antimalarial compounds","volume":"8","author":"Istvan","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jgar.2021.10.030_bib0016","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/molecules25061451","article-title":"New cysteine protease inhibitors: electrophilic (het)arenes and unexpected prodrug identification for the Trypanosoma protease rhodesain","volume":"25","author":"Klein","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jgar.2021.10.030_bib0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd1606","article-title":"In vivo drug discovery in the zebrafish","volume":"4","author":"Zon","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jgar.2021.10.030_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00401-18","article-title":"Outcome of E1224\u2013benznidazole combination treatment for infection with a multidrug-resistant Trypanosoma cruzi strain in mice","volume":"62","author":"Diniz","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.030_bib0019","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/AAC.00404-16","article-title":"Clomipramine and benznidazole act synergistically and ameliorate the outcome of experimental Chagas disease","volume":"60","author":"Garc\u00eda","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.030_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/0074-02760170267","article-title":"Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment","volume":"113","author":"Aguilera","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:58:35Z","timestamp":1761991115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":20,"alternative-id":["S2213716521002794"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.030","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prodrugs as new therapies against Chagas disease: in vivo synergy between Trypanosoma cruzi proline racemase inhibitors and benznidazole","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}